Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daiichi Sankyo’s Edoxaban Could Find Role In Treating Sickest Patients

This article was originally published in PharmAsia News

Executive Summary

Firm’s Factor Xa inhibitor demonstrates equal efficacy to warfarin with lower overall clinically relevant bleeding in a Phase III study; drug works well even in patients with right ventricular dysfunction, a sign of more serious pulmonary embolism.

You may also be interested in...

Bayer Sees Xarelto Being Profitable In 2014 As New Drugs Deliver

Bayer’s pharma sales surged in the second quarter, driven by heart drug Xarelto, new ophthalmic Eylea and cancer treatment Stivarga, prompting the German blue chip to raise its sales forecast for medicines this year and assert that its new oral anticoagulant probably will become profitable in 2014.

Xarelto Filing Puts It Out Ahead In Venous Thromboembolism

Though other novel anticoagulants are in development for treatment and prevention of venous thromboembolism, Janssen and its partner Bayer are hoping Xarelto will be coming out ahead.

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts